Drug Development Program
Rare Diseases
ResearchEarly Development
Key Facts
About MindMaze Therapeutics
MindMaze Therapeutics, founded in 2012, is on a mission to transform the treatment and management of neurological diseases through its innovative 'neurotherapeutic combinations.' The company has achieved significant commercial traction with FDA-cleared systems deployed in leading clinical centers globally, treating thousands of patients and delivering hundreds of thousands of therapy sessions. Its strategy leverages a proprietary platform that merges behavioral interventions, software, devices, and data analytics into a cohesive ecosystem, positioning it at the forefront of digital neurotherapeutics and precision brain health.
View full company profileTherapeutic Areas
Other Rare Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| RareScan | Constantiam Bio | Research |
| Undisclosed Rare Disease Program(s) | Base4 | Preclinical |
| Prognos Rare Disease | Prognos | Commercial |
| PEPRX101 | Peptris Technologies Private | In-vitro |